Skip to content

Dynamic Area Telethermometry (DAT) as an Imaging Modality in Patients With Cancer

Dynamic Area Telethermometry (DAT) as an Auxiliary Imaging Modality in Assessment of Patients With Cancer

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00165100
Enrollment
50
Registered
2005-09-14
Start date
2000-01-31
Completion date
2002-10-31
Last updated
2007-12-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lymph Node Tumors, Malignant Tumors, Subcutaneous Tumors

Keywords

DAT, imaging modality

Brief summary

The purpose of this study is to evaluate whether this new method of taking pictures called Dynamic Area Telethermometry (DAT) might be a good way of looking at patients with cancer that is relatively close to the surface of the body.

Detailed description

* The DAT system resembles a video camera which picks up changes in body temperature which may reflect disease-related changes in blood flow to some areas, particularly those involved with tumors. * Patients with known tumor sites amendable to DAT evaluation will be imaged at the time of staging and at later time points. Thermal profiles will be compared to those of normal adjacent tissues and correlated with the images of the tumors on conventional images.

Interventions

PROCEDUREDynamic Area Telethermometry (DAT)

Sponsors

Brigham and Women's Hospital
CollaboratorOTHER
Dana-Farber Cancer Institute
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
16 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Histologically confirmed malignancy * Primary or secondary tumor location amendable to DAT scanning: subcutaneous tissues * Older than 15 years of age * Able to withhold movement for 20 seconds, hold breath for 20 seconds for chest wall lesions and clinically stable acutely

Exclusion criteria

* Uncontrolled motion * Tumors not verified or measurable by standard imaging

Design outcomes

Primary

MeasureTime frame
To assess the feasibility of DAT in tumors detected by conventional imaging and evaluation of therapy induced changes in DAT imaging profile over time.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026